REZOLUTE, INC. (RZLT) EBITDA
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$17.37M; Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA (m); Operating income -$24.22M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$19.82M; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income -$20.02M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Reported | (m) | -$17.37M | (m) | (m) | (m) | (m) | -$13.73M* | (m) | $11.41M | (m) | (m) |
| 2025-12-31 | Reported | (m) | -$24.22M | (m) | (m) | (m) | (m) | -$20.32M* | (m) | $14.35M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$19.82M | (m) | (m) | (m) | (m) | -$17.43M | (m) | $13.15M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$20.02M | (m) | (m) | (m) | (m) | -$17.40M* | (m) | $15.28M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$17.08M | (m) | (m) | (m) | (m) | -$13.67M* | (m) | $12.63M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$16.94M | (m) | (m) | (m) | (m) | -$16.01M | (m) | $12.75M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$16.21M | (m) | (m) | (m) | (m) | -$15.24M* | (m) | $12.40M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$15.19M | (m) | (m) | (m) | (m) | -$13.02M* | (m) | $12.04M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$15.91M | (m) | (m) | (m) | (m) | -$10.59M | (m) | $12.21M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$17.14M | (m) | (m) | (m) | $0.00* | -$18.05M* | (m) | $14.23M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$14.39M | (m) | (m) | (m) | $83.00K* | -$7.49M* | (m) | $10.95M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$10.22M | (m) | (m) | (m) | $70.00K | -$7.59M | (m) | $7.70M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$10.75M | (m) | (m) | (m) | (m) | -$13.97M* | (m) | $8.69M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$12.15M | (m) | (m) | (m) | (m) | -$7.20M* | (m) | $9.45M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$7.64M | (m) | (m) | (m) | (m) | -$6.34M | (m) | $5.77M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$5.48M | (m) | (m) | (m) | (m) | -$5.40M* | (m) | $3.76M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$7.15M | (m) | (m) | (m) | (m) | -$6.26M* | (m) | $4.50M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$3.62M | (m) | (m) | (m) | (m) | -$3.55M | (m) | $2.34M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$5.07M | (m) | (m) | (m) | (m) | -$5.68M* | (m) | $3.73M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$6.72M | (m) | (m) | (m) | (m) | -$5.48M* | (m) | $5.04M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$5.18M | (m) | (m) | (m) | (m) | -$8.93M | (m) | $3.23M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$17.04M | (m) | (m) | (m) | (m) | -$8.46M* | (m) | $15.12M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$3.16M | (m) | (m) | (m) | (m) | -$1.65M* | (m) | $1.31M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$2.56M | (m) | (m) | (m) | (m) | -$1.43M | (m) | $930.00K | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$4.95M | (m) | (m) | (m) | (m) | -$2.18M* | (m) | $2.50M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$5.75M | (m) | (m) | (m) | (m) | -$3.15M* | (m) | $3.41M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$6.72M | (m) | (m) | (m) | (m) | -$4.91M | (m) | $4.31M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$5.39M | (m) | (m) | (m) | (m) | -$3.61M* | (m) | $3.44M | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$4.89M | (m) | (m) | (m) | (m) | -$3.09M* | (m) | $3.08M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$3.82M | (m) | (m) | (m) | (m) | -$2.97M | (m) | $2.49M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$3.72M | (m) | (m) | (m) | (m) | (m) | (m) | $2.31M | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$4.07M | (m) | (m) | (m) | (m) | (m) | (m) | $2.52M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$3.30M | (m) | (m) | (m) | (m) | (m) | (m) | $1.97M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$2.30M | (m) | (m) | (m) | (m) | (m) | (m) | $1.29M | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$3.07M | (m) | (m) | (m) | (m) | (m) | (m) | $1.57M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$2.24M | (m) | (m) | (m) | (m) | (m) | (m) | $112.56K | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$1.60M | (m) | (m) | (m) | (m) | -$707.58K* | (m) | $2.25K | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$650.12K | (m) | (m) | (m) | (m) | -$365.27K* | (m) | $0.00 | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$700.90K | (m) | (m) | (m) | (m) | $3.67K | (m) | $0.00 | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$4.05M | (m) | (m) | (m) | (m) | -$651.67K* | (m) | $3.02K | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$500.06K | (m) | (m) | (m) | (m) | -$398.51K* | (m) | $0.00 | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$542.88K | (m) | (m) | (m) | (m) | -$345.04K | (m) | $0.00 | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$94.60K | (m) | (m) | (m) | (m) | -$440.65K* | (m) | $0.00 | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$82.97M | (m) | (m) | (m) | (m) | -$64.64M | (m) | $53.80M | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$79.89M | (m) | (m) | (m) | (m) | -$69.08M | (m) | $61.53M | (m) | $0.00 |
| 2024-06-30 | Reported | (m) | -$70.42M | (m) | (m) | (m) | (m) | -$57.37M | (m) | $55.74M | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$55.99M | (m) | (m) | (m) | $153.00K | -$44.48M | (m) | $43.81M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$41.84M | (m) | (m) | (m) | (m) | -$39.62M | (m) | $32.49M | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$22.89M | (m) | (m) | (m) | (m) | -$20.44M | (m) | $14.99M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$20.52M | (m) | (m) | (m) | $0.00 | -$24.17M | (m) | $14.45M | (m) | $0.00 |
| 2019-06-30 | Reported | (m) | -$25.94M | (m) | (m) | (m) | $47.00K | -$15.30M | (m) | $19.08M | (m) | $0.00 |
| 2018-06-30 | Reported | (m) | -$28.73M | (m) | (m) | (m) | $6.00K | -$14.11M | (m) | $17.28M | (m) | $0.00 |
| 2017-06-30 | Reported | (m) | -$20.32M | (m) | (m) | (m) | (m) | -$13.31M | (m) | $12.09M | (m) | $0.00 |
| 2016-06-30 | Reported | (m) | -$14.95M | (m) | (m) | (m) | (m) | (m) | (m) | $9.45M | (m) | $0.00 |
| 2015-06-30 | Reported | (m) | -$10.70M | (m) | (m) | (m) | (m) | (m) | (m) | $4.70M | (m) | $0.00 |
| 2014-06-30 | Reported | (m) | -$5.18M | (m) | (m) | (m) | (m) | (m) | (m) | $34.32K | (m) | $0.00 |
| 2013-06-30 | Reported | (m) | -$6.11M | (m) | (m) | (m) | (m) | -$1.63M | (m) | $3.49K | (m) | $0.00 |
| 2011-12-31 | Reported | (m) | -$392.98K | (m) | (m) | (m) | (m) | -$363.22K | (m) | $0.00 | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |